The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003

被引:376
作者
Lehman, AF
Kreyenbuhl, J
Buchanan, RW
Dickerson, FB
Dixon, LB
Goldberg, R
Green-Paden, LD
Tenhula, WN
Boerescu, D
Tek, C
Sandson, N
Steinwachs, DM
机构
[1] Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA
[2] MIRECC, VA Capital Hlth Care Network, Baltimore, MD USA
[3] Sheppard Pratt Hlth Syst, Div Educ & Residency Training, Baltimore, MD USA
[4] Rhode Isl Hosp, Dept Psychiat, Providence, RI 02903 USA
[5] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA
[6] Johns Hopkins Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21218 USA
关键词
schizophrenia; mental health services; quality of care; treatment outcomes; pharmaeotherapy; psychosocial treatment;
D O I
10.1093/oxfordjournals.schbul.a007071
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Since publication of the original Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations in 1998, considerable scientific advances have occurred in our knowledge about how to help persons with schizophrenia. Today an even stronger body of research supports the scientific basis of treatment. This evidence, taken in its entirety, points to the value of treatment approaches combining medications with psychosocial treatments, including psychological interventions, family interventions, supported employment, assertive community treatment, and skills, training. The most significant advances lie in the increased options for pharmacotherapy, with the introduction of second generation antipsychotic medications, and greater confidence and specificity in the application of psychosocial. interventions. Currently available treatment technologies, when appropriately applied and accessible, should provide most patients with significant relief from psychotic symptoms and improved opportunities to lead more fulfilling lives in the community. Nonetheless, major challenges remain, including the need for (1) better knowledge about the underlying etiologies of the neurocognitive impairments and deficit symptoms that account for much of the disability still associated with schizophrenia; (2) treatments that more directly address functional impairments and that promote recovery; and (3) approaches that facilitate access to scientifically based treatments for patients, the vast majority of whom currently do not have such access.
引用
收藏
页码:193 / 217
页数:25
相关论文
共 217 条
  • [1] Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia
    Addington, D
    Addington, J
    Patten, S
    Remington, G
    Moamai, J
    Labelle, A
    Beauclair, L
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (01) : 20 - 25
  • [2] Successful treatment of tardive dystonia with clozapine
    Adityanjee
    Estrera, AB
    [J]. BIOLOGICAL PSYCHIATRY, 1996, 39 (12) : 1064 - 1065
  • [3] Allan ER, 1998, PSYCHOPHARMACOL BULL, V34, P71
  • [4] Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia
    Alptekin, K
    Kivircik, BB
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (05) : 263 - 264
  • [5] *AM PSYCH ASS, 1997, PRACT GUID TREATM PA
  • [6] Tardive dyskinesia associated with olanzapine monotherapy
    Ananth, J
    Kenan, J
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (12) : 870 - 870
  • [7] [Anonymous], 1977, Psychosocial treatment of chronic mental patients: Milieu versus social learning program
  • [8] Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
    Arvanitis, LA
    Miller, BG
    Borison, RL
    Pitts, WM
    Sharif, ZA
    Hamner, MB
    Herz, MI
    True, JE
    Velligan, D
    Knesevich, MA
    Small, J
    Steinbook, R
    Hertzman, M
    Keck, PE
    Newcomer, JW
    Grace, J
    Rotrosen, J
    Tandon, R
    Dott, SG
    Ferguson, JM
    Addington, DEN
    MacEwan, GW
    Nair, VNP
    Shriqui, CL
    Williams, R
    Daniel, DG
    Shehi, GM
    Patterson, WM
    Merideth, CH
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (04) : 233 - 246
  • [9] MEDICAL-PRACTICE GUIDELINES - CURRENT ACTIVITIES AND FUTURE-DIRECTIONS
    AUDET, AM
    GREENFIELD, S
    FIELD, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 113 (09) : 709 - 714
  • [10] A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
    Azorin, JM
    Spiegel, R
    Remington, G
    Vanelle, JM
    Péré, JJ
    Giguere, M
    Bourdeix, I
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (08) : 1305 - 1313